The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial

Autor: Kiki J. A. Frencken, Axel zur Hausen, Tjinta Brinkhuizen, Véronique Winnepenninckx, Maurice A.M. van Steensel, Dorit Rennspiess, Patricia J. Nelemans, Michiel P. J. van der Horst, Klara Mosterd, Nicole W.J. Kelleners-Smeets, Marlou L. S. Hoff
Přispěvatelé: MUMC+: MA AIOS Dermatologie (9), Promovendi ODB, Dermatologie, Epidemiologie, RS: CAPHRI - R5 - Optimising Patient Care, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Dermatologie (9), MUMC+: DA Klinische Pathologie (5), Pathologie, RS: GROW - R2 - Basic and Translational Cancer Biology, MUMC+: DA Pat Pathologie (9)
Rok vydání: 2015
Předmět:
Male
Pathology
Skin Neoplasms
Administration
Topical

vitamin D
Apoptosis
Gastroenterology
law.invention
Ointments
030207 dermatology & venereal diseases
0302 clinical medicine
Randomized controlled trial
law
Medicine
Single-Blind Method
topical
Anti-Inflammatory Agents
Non-Steroidal

Diclofenac Sodium
Vitamins
Middle Aged
targeted therapy
Treatment Outcome
Proto-Oncogene Proteins c-bcl-2
030220 oncology & carcinogenesis
Drug Therapy
Combination

Female
medicine.drug
medicine.medical_specialty
Diclofenac
Calcitriol
Combination therapy
Dermatology
Medication Adherence
03 medical and health sciences
basal cell carcinoma
Internal medicine
noninvasive
Humans
Basal cell carcinoma
Adverse effect
Aged
Cell Proliferation
nonsteroidal anti-inflammatory drugs
business.industry
medicine.disease
Lymphoma
stomatognathic diseases
Ki-67 Antigen
Carcinoma
Basal Cell

business
Gels
Zdroj: Journal of the American Academy of Dermatology, 75(1), 126-134. MOSBY-ELSEVIER
ISSN: 1097-6787
0190-9622
Popis: Background: Nonsteroidal anti-inflammatory drugs and vitamin-D derivatives can target signaling pathways activated in basal cell carcinoma (BCC). Objective: We investigated the efficacy of topically applied diclofenac sodium 3% gel, calcitriol 3 mu g/g ointment, and a combination of both in superficial BCC (sBCC) and nodular BCC. Methods: Patients with a primary, histologically proven sBCC (n = 64) or nodular BCC (n = 64) were randomized to topical diclofenac, calcitriol, combination of both, or no topical treatment (control group). After self-application twice daily under occlusion (8 weeks), tumors were excised. Primary outcome was posttreatment expression levels of proliferation (Ki-67) and antiapoptosis (B-cell lymphoma [Bcl-2]) immunohistochemical markers. Secondary outcomes were histologic clearance, adverse events, application-site reactions, and patient compliance. Results: sBCC treated with diclofenac showed a significant decrease in Ki-67 (P
Databáze: OpenAIRE